CLINICAL TRIALS PROFILE FOR BEMPEDOIC ACID
✉ Email this page to a colleague
All Clinical Trials for bempedoic acid
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02666664 ↗ | Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony) | Completed | Esperion Therapeutics | Phase 3 | 2016-01-21 | The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy. |
| NCT02666664 ↗ | Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony) | Completed | Esperion Therapeutics, Inc. | Phase 3 | 2016-01-21 | The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy. |
| NCT02988115 ↗ | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant | Completed | Esperion Therapeutics | Phase 3 | 2016-11-16 | The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant. |
| NCT02988115 ↗ | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant | Completed | Esperion Therapeutics, Inc. | Phase 3 | 2016-11-16 | The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant. |
| NCT02991118 ↗ | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk | Completed | Esperion Therapeutics | Phase 3 | 2016-11-18 | The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy. |
| NCT02991118 ↗ | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk | Completed | Esperion Therapeutics, Inc. | Phase 3 | 2016-11-18 | The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy. |
| NCT02993406 ↗ | Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo | Active, not recruiting | The Cleveland Clinic | Phase 3 | 2016-11-18 | The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for bempedoic acid
Condition Name
Clinical Trial Locations for bempedoic acid
Trials by Country
Clinical Trial Progress for bempedoic acid
Clinical Trial Phase
Clinical Trial Sponsors for bempedoic acid
Sponsor Name
